MLi-2 |
Catalog No.GC30769
One-Click Copy Product Info
|
MLi-2 is a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), with an IC₅₀ value of 0.76nM. MLi-2 exhibits excellent central nervous system penetration and serves as an important tool compound for studying LRRK2 function and the pathological mechanisms of Parkinson’s disease (PD).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1627091-47-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MLi-2 is a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), with an IC₅₀ value of 0.76nM [1]. MLi-2 exhibits excellent central nervous system penetration and serves as an important tool compound for studying LRRK2 function and the pathological mechanisms of Parkinson’s disease (PD)[2-3]. Additionally, MLi-2 has been shown to alleviate DOPA-responsive dystonia[4].
In vitro, treatment with MLi-2 (100nM) for 2 hours in SH-SY5Y and MEF cells expressing either wild-type or 4xSA (S910A/S935A/S955A/S973A) mutant LRRK2 significantly inhibited LRRK2 kinase activity, as evidenced by a marked reduction in the phosphorylation levels of Rab8a (T72) and Rab10 (T73), as well as decreased autophosphorylation of LRRK2 at residues S910, S935, S955, and S973[5]. MLi-2 (1μM) treatment for 24 hours in primary microglia derived from wild-type and G2019S-LRRK2 mice significantly reduced LRRK2 phosphorylation at Ser935, indicating effective inhibition of LRRK2 kinase activity. RNA-Seq analysis revealed that MLi-2 treatment primarily upregulated genes associated with the regulation of ion transmembrane transport and downregulated genes involved in the positive regulation of apoptosis[6].
In vivo, MLi-2 (8 or 45mg/kg/day) was administered via diet to wild-type and LRRK2 G2019S knock-in mice injected with Alzheimer’s disease-derived tau fibrils. Treatment began one week prior to tau injection and continued for 6 months. MLi-2 significantly reduced tau pathology progression in cortical regions of G2019S mutant mice, with the effect being more pronounced at the 45mg/kg/day dose. MLi-2 also reversed the altered direction of pathology spread caused by the G2019S mutation. Additionally, long-term MLi-2 treatment led to enlargement of pneumocytes in the lungs[7]. MLi-2 (10mg/kg) was administered via intraperitoneal injection to 12-month-old LRRK2 G2019S knock-in (KI) mice to assess its effects on dopamine transporter (DAT) function. Although MLi-2 significantly inhibited LRRK2 kinase activity (as shown by a 75% reduction in pSer1292 LRRK2 levels), MLi-2 failed to reverse the abnormally elevated DAT uptake activity (Vmax) observed in G2019S KI mice[8].
References:
[1] Fell MJ, Mirescu C, Basu K, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409.
[2] Hatcher JM, Zwirek M, Sarhan AR, et al. Development of a highly potent and selective degrader of LRRK2. Bioorg Med Chem Lett. 2023 Oct 1;94:129449.
[3] Tengberg JF, Russo F, Benned-Jensen T, et al. LRRK2 and RAB8A regulate cell death after lysosomal damage in macrophages through cholesterol-related pathways. Neurobiol Dis. 2024 Nov;202:106728.
[4] Roman KM, Dinasarapu AR, Cherian S, et al. Striatal cell-type-specific molecular signatures reveal potential therapeutic targets in a model of dystonia. Neurobiol Dis. 2025 Aug;212:106981.
[5] Kania E, Long JS, McEwan DG, et al. LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner. Cell Death Dis. 2023 Jul 15;14(7):436.
[6] Nazish I, Mamais A, Mallach A, et al. Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2. Cells. 2023 Dec 26;13(1):53.
[7] Lubben N, Brynildsen JK, Webb CM, et al. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression. Transl Neurodegener. 2024 Mar 4;13(1):13.
[8] Domenicale C, Mercatelli D, Albanese F, et al. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice. Biomedicines. 2022 Apr 12;10(4):881.
| Cell experiment [1]: | |
Cell lines | Primary microglia from wild-type and LRRK2 G2019S knock-in mice |
Preparation Method | Primary microglia were isolated from postnatal day 1–2 mouse brains and cultured for approximately 10 days. Cells were then treated with zymosan (200µg/mL) and/or MLi-2(1µM) for 24 hours to assess inflammatory and transcriptional responses. |
Reaction Conditions | 1µM MLi-2; 24 hours |
Applications | MLi-2 significantly inhibited LRRK2 kinase activity, as shown by reduced phosphorylation at Ser935, and modulated gene expression profiles, particularly upregulating genes involved in ion transmembrane transport regulation and downregulating genes related to apoptotic processes in both wild-type and G2019S-LRRK2 microglia. |
| Animal experiment [2]: | |
Animal models | LRRK2G2019S knock-in mice and wild-type littermates (C57BL/6 background) |
Preparation Method | Mice were injected unilaterally with tau paired helical filaments (PHFs) derived from Alzheimer’s disease brains into the hippocampus and overlying cortex at 3–4 months of age. One week prior to injection, mice were placed on a control diet or a diet containing the LRRK2 kinase inhibitor MLi-2 at doses of 8mg/kg or 45mg/kg. Mice were maintained on the diet for 6 months post-injection before sacrifice and brain tissue analysis. |
Dosage form | 8mg/kg/day or 45mg/kg/day; administered orally via diet. |
Applications | MLi-2 reduced total and phosphorylated LRRK2 (pS935) levels in kidney tissue, indicating target engagement. It induced enlargement of type II pneumocytes in the lungs, consistent with known LRRK2 inhibition-related morphological changes. In LRRK2G2019S mice, MLi-2 reversed the mutation-associated acceleration of tau pathology progression, particularly in cortical brain regions, without significantly affecting tau pathology in wild-type mice. These effects were more pronounced at 6 months post-injection and with the higher dose (45mg/kg/day), suggesting a dose- and time-dependent therapeutic effect in LRRK2 mutation carriers. |
References: | |
| Cas No. | 1627091-47-7 | SDF | |
| Canonical SMILES | C[C@@](C1)([H])O[C@](C)([H])CN1C2=CC(C3=NNC4=CC=C(OC5(C)CC5)C=C43)=NC=N2 | ||
| Formula | C21H25N5O2 | M.Wt | 379.46 |
| Solubility | DMSO : ≥ 26 mg/mL (68.52 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6353 mL | 13.1766 mL | 26.3532 mL |
| 5 mM | 527.1 μL | 2.6353 mL | 5.2706 mL |
| 10 mM | 263.5 μL | 1.3177 mL | 2.6353 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)